
Please note that the information in this Safety log is correct at the time of publication. Clinicians should always refer to the most up to date information.

Copyright © Midlands and Lancashire Commissioning Support Unit

Medicines Safety Assurance Tool June 2018





European CHMP endorses measurers to reduce risk of liver injury with ulipristal acetate (Esmya) European Medicines Agency 04 June 2018 New measures have been placed to highlight contraindications in liver problems. It is advised to do liver tests before, during and after stopping treatment. There should be a patient card detailing liver monitoring and to contact GP if symptomatic. Additionally, use of for more than one treatment course is restricted to women not eligible for surgery. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news and events/news/2018/06/	Proposed action Newsletter Practice audit/search Action taken	Optimise Rx/ScriptSwi	
	Status Unassigned ▼	Action due date	Date completed
Can small volume intramuscular injections be given to patients taking oral anticoagulants? Specialist Pharmacy Service 12 June 2018 Q+A notes most of published studies relate to IM influenza vaccination in patients on older anticoagulants. Data are limited, and	Proposed action Newsletter Practice audit/search	Optimise Rx/ScriptSwi	
some findings are contradictory. There is very little published information about the risks of adverse effects with DOACs and IM injections. https://www.sps.nhs.uk/articles/can-small-volume-intramuscular-injections-be-given-to-patients-taking-oral-anticoagulants/			
	Action taken		
	Status	Action due date	Date completed
	Unassigned 🔻		

What factors need to be considered when dosing patients with renal impairment? Specialist Pharmacy Service 18 June 2018 his article discusses the pharmacokinetic and pharmacodynamic factors that affect dosing in renal impairment. https://www.sps.nhs.uk/wp-content/uploads/2018/06/SW-QA-Dosing in RI- 2018.docx	Proposed action Newsletter Practice audit/search Action taken	Optimise Rx/ScriptSwi Other (please specify)	
	Status Unassigned ▼	Action due date	Date completed
Resources to support safer modification of food and drink Central Alerting System 27 June 2018 This alert has been released to highlight the variation in the terminology used to describe the thickness of modified food for patients with dysphagia. https://www.cas.mhra.gov.uk/ViewAndAcknowledgment/viewAlert.aspx?AlertID=102767	Proposed action Newsletter Practice audit/search	Optimise Rx/ScriptSwi Other (please specify)	
	Action taken		
	Status Unassigned ▼	Action due date	Date completed

Summary of Product Characteristics Update

Electronic Medicines Compendium | June 2018

Coversyl Arginine (perindopril arginine)

New contraindications (bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney, extracorporeal treatments and use with sacubitril/valsartan), and an interaction with co-trimoxazole (concomitant use may increase risk of hyperkalaemia).

https://www.medicines.org.uk/emc/product/6224/smpc

Eliquis (apixaban) 2.5mg film-coated tablets

The SPC has been updated to state that 'apixaban can be initiated or continued in NVAF patients who may require cardioversion'. Information has also been added to include detail on dose in relation to cardioversion. Data from the EMANATE study (conducted in patients undergoing cardioversion) has been added.

https://www.medicines.org.uk/emc/product/4756/smpc

Epilim/Zentiva (valproate) healthcare professional letter

The letter sets out new contraindications, warnings and measures from the EMA and MHRA to prevent valproate exposure during pregnancy.

https://www.medicines.org.uk/emc/rmm/1231/Document

Hiprex (methenamine) tablets

It has been noted that methenamine affects the urine test results when testing for steroids, catecholamines and 5 hydroxyindole acetic acid and that it is preferred to avoid it during pregnancy as a precaution. Side effects of diarrhoea and abdominal pain have been added.

https://www.medicines.org.uk/emc/product/1530/smpc

Invokana (canagliflozin) 100mg and 300mg film coated tablets

SPC has included study data which has evaluated canagliflozin in combination with metformin and sitagliptin and a study also done to evaluate it in combination with metformin XR.

https://www.medicines.org.uk/emc/product/8855/smpc

Proposed action Newsletter Practice audit/search	Optimise Rx/Sc	•
Action taken		
Status	Action due date	Date completed
Unaccianad		

Iopidine (apraclonidine) 5mg/ml eye drops, solution

Hypersensitivity and eyelid disorder have been added as adverse drug reactions.

https://www.medicines.org.uk/emc/product/838/smpc

Janumet (sitagliptin and metformin) tablets

Adverse effect of thrombocytopenia has been added as a rare potential effect.

https://www.medicines.org.uk/emc/product/564/smpc

Januvia (sitagliptin)

Thrombocytopenia has been added as a rare adverse event.

https://www.medicines.org.uk/emc/product/321/smpc

Ketovite tablets

Anaphylactic reaction has been added to SPC as an adverse effect of unknown frequency.

https://www.medicines.org.uk/emc/product/1052/smpc

Nurofen for Children (ibuprofen; various products)

Adverse drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) has been added as an adverse effect, with the frequency unknown.

https://www.medicines.org.uk/emc/product/396/smpc

PecFent (fentanyl citrate)

The SPC states that there is a possibility of hyperalgesia, tolerance and progression of disease should be considered in the absence of adequate pain control. Drug dependence and neonatal withdrawal syndrome have been added as unknown frequency adverse drug reactions.

https://www.medicines.org.uk/emc/product/5782/smpc

Propecia (finasteride) 1mg tablets

An adverse reaction of anxiety has been added as an unknown frequency.

https://www.medicines.org.uk/emc/product/2194/smpc

Proscar (finasteride) 5mg film coated tablets

An adverse drug reaction of 'anxiety' of unknown frequency has been added to SPC. https://www.medicines.org.uk/emc/product/1008/smpc

Scheriproct ointment and suppositories

There is a new warning that the following excipients in ointment and suppositories may reduce the effectiveness of latex products such as condoms; castor oil refined, castor oil hydrogenated, macrogol-400-monoricinoleate and perfume oil chypre. https://www.medicines.org.uk/emc/product/283/smpc

Siklos (hydroxycarbamide) Film coated tablets - all strengths

Section 4.8 now warns systemic and cutaneous lupus erythematosus as very rare adverse reactions. https://www.medicines.org.uk/emc/product/4033/smpc

Starlix (nateglinide) 60mg film coated tablets

SPC has been updated to state that patients with severe renal impairment who have not undergone haemodialysis, are more susceptible to its glucose-lowering effect. Therefore, discontinuation of the product should be considered in patients with severe renal impairment who present with potentiation of the hypoglycaemic event.

https://www.medicines.org.uk/emc/product/1320/smpc

Symbicort (budesonide and formoterol fumarate) pressurised inhalation, suspension

Instructions and pharmacokinetic data for when Symbicort is used with a spacer device has been updated on the SPC. https://www.medicines.org.uk/emc/product/7223/smpc

Education Risk Minimisation Materials to help reduce the risk associated with using Truvada (tenofovir disoproxil fumarate/emtricitabine) film coated tablets

This guidance document has been amended to include advice specific to adolescents following extension to indication for use with safer sex practices for PrEP in those at high risk aged 12 years and above, weighing 35kg or more. https://www.medicines.org.uk/emc/product/3890/rmms

Valcyte (valganciclovir) 450mg film coated tablets

The SPC has included information on a small clinical study that evaluated the effect of valganciclovir on spermatogenesis and noted that a higher risk of cytopenia in neonates and infants requires careful monitoring of blood counts in these age groups. https://www.medicines.org.uk/emc/product/1641/smpc

Vipidia (alogliptin) tablets

Diarrhoea has been added as a common potential adverse effect.

https://www.medicines.org.uk/emc/product/5235/smpc

Zidoval (metronidazole) vaginal gel

It has been noted that metronidazole has found to be carcinogenic in certain animal species, however, this has not been established in human. The effect of topical metronidazole on prothrombin time is also not known. https://www.medicines.org.uk/emc/product/830/smpc

Zirtek Allergy (cetirizine) 10mg film coated tablets

An adverse effect of Hepatitis has been added with unknown frequency https://www.medicines.org.uk/emc/product/6751/smpc

Zithromax (Azithromycin) – all formulations

An interaction with colchicine has been added; concomitant administration has been reported to result in increased serum levels of the P-glycoprotein substrate.

https://www.medicines.org.uk/emc/product/9205/smpc